SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer

Keyphrases

• Bone Metastasis 100%
• Tumor Growth 100%
• Breast Cancer 100%
• Prostate Cancer 100%
• Kinase Inhibition 100%
• Bone Tumor 100%
• Osteoclast 66%
• Bone Lesions 66%
• Clinical Trials 33%
• Clinical Setting 33%
• Solid Tumors 33%
• Tumor Metastasis 33%
• Preclinical Data 33%
• Specific Activity 33%
• Breast Cancer Cells 33%
• Signaling Molecules 33%
• Bone Resorption 33%
• Clinical Benefit 33%
• Complex Interactions 33%
• Targeted Agents 33%
• Metastasizing 33%
• Receptor Signaling 33%
• Prostate Cancer Cells 33%
• Receptor Tyrosine Kinase 33%
• Inhibit Tumor 33%
• Patients with Breast Cancer 33%
• Clinical Development 33%
• Advanced Disease 33%
• Metastatic Breast Cancer 33%
• Osteoblast 33%
• Tumor Response 33%
• Patients with Prostate Cancer 33%
• Patient Morbidity 33%
• Hormone Receptor 33%
• Tumor-associated 33%
• Treatment Goals 33%
• Tumor Bone 33%
• Bone Pathology 33%
• Dasatinib 33%
• Phase 1/2 Clinical Trial 33%
• Metastatic Prostate Cancer 33%

Medicine and Dentistry

• Tumor Progression 100%
• Breast Cancer 100%
• Bone Cancer 100%
• Bone Metastasis 100%
• Phosphotransferase 100%
• Prostate Cancer 100%
• Metastatic Carcinoma 75%
• Neoplasm 50%
• Osteoclast 50%
• Bone Lesion 50%
• Clinical Trial 25%
• Solid Malignant Neoplasm 25%
• Cancer Cell 25%
• Morbidity 25%
• Osteolysis 25%
• Tumor Cell 25%
• Protein Tyrosine Kinase 25%
• Osteoblast 25%
• Signaling Molecule 25%
• Hormone Receptor 25%
• Bone Pathology 25%
• Bosutinib 25%
• Saracatinib 25%
• Dasatinib 25%
• Diseases 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Bone Metastasis 100%
• Tumor Growth 100%
• Bone Tumor 100%
• Bone Cancer 100%
• Phosphotransferase 100%
• Prostate Cancer 100%
• Neoplasm 50%
• Bone Lesion 50%
• Solid Malignant Neoplasm 25%
• Clinical Trial 25%
• Protein Tyrosine Kinase 25%
• Morbidity 25%
• Hormone Receptor 25%
• Saracatinib 25%
• Dasatinib 25%
• Bosutinib 25%
• Diseases 25%